Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial.

Authors : Lopes Cardozo JMN, Byng D, Drukker CA, Schmidt MK, Binuya MA, van t Veer LJ, Cardoso F, Piccart M, Smorenburg CH, Poncet C, Rutgers EJT
Year : 2022
Journal : Ann Oncol
Volume : 33
Pages : 310-320